Teva Pharmaceutical Industries Limited (NYSE:TEVA) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has been assigned a consensus recommendation of “Moderate Buy” from the eight ratings firms that are covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $17.00.

A number of equities analysts have commented on TEVA shares. StockNews.com downgraded shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Monday, May 20th. Bank of America upped their price objective on shares of Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the stock a “buy” rating in a research note on Thursday, May 30th. Jefferies Financial Group upped their price target on shares of Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 target price for the company in a report on Friday, March 8th. Finally, Piper Sandler restated an “overweight” rating and set a $20.00 price objective (up from $19.00) on shares of Teva Pharmaceutical Industries in a research note on Monday, May 13th.

Teva Pharmaceutical Industries Stock Up 0.5 %

Shares of NYSE TEVA opened at $16.33 on Thursday. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.20. Teva Pharmaceutical Industries has a 12-month low of $7.42 and a 12-month high of $17.69. The firm’s 50-day moving average price is $16.06 and its 200-day moving average price is $13.75. The stock has a market capitalization of $18.50 billion, a price-to-earnings ratio of -39.83, a P/E/G ratio of 1.54 and a beta of 0.90.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, May 8th. The company reported $0.46 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.03). Teva Pharmaceutical Industries had a positive return on equity of 37.33% and a negative net margin of 2.88%. The company had revenue of $3.82 billion during the quarter, compared to the consensus estimate of $3.70 billion. On average, equities research analysts anticipate that Teva Pharmaceutical Industries will post 2.32 EPS for the current fiscal year.

Insider Activity at Teva Pharmaceutical Industries

In related news, insider Vikki L. Conway sold 15,219 shares of the firm’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $16.74, for a total transaction of $254,766.06. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other Teva Pharmaceutical Industries news, CAO Amir Weiss sold 15,500 shares of the company’s stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $16.80, for a total transaction of $260,400.00. Following the completion of the transaction, the chief accounting officer now directly owns 17,814 shares in the company, valued at $299,275.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Vikki L. Conway sold 15,219 shares of the stock in a transaction on Monday, May 13th. The shares were sold at an average price of $16.74, for a total transaction of $254,766.06. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 549,719 shares of company stock worth $9,353,736. 0.55% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. increased its holdings in shares of Teva Pharmaceutical Industries by 705.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 579,562 shares of the company’s stock valued at $6,051,000 after purchasing an additional 507,568 shares during the last quarter. SG Americas Securities LLC grew its holdings in shares of Teva Pharmaceutical Industries by 31.7% in the fourth quarter. SG Americas Securities LLC now owns 544,878 shares of the company’s stock valued at $5,689,000 after purchasing an additional 131,043 shares during the period. Wellington Management Group LLP increased its position in Teva Pharmaceutical Industries by 42.2% during the third quarter. Wellington Management Group LLP now owns 344,587 shares of the company’s stock worth $3,515,000 after purchasing an additional 102,261 shares during the last quarter. Gateway Investment Advisers LLC boosted its holdings in Teva Pharmaceutical Industries by 28.6% in the 4th quarter. Gateway Investment Advisers LLC now owns 41,882 shares of the company’s stock valued at $437,000 after purchasing an additional 9,312 shares during the last quarter. Finally, Public Employees Retirement Association of Colorado grew its stake in shares of Teva Pharmaceutical Industries by 1,382.8% in the 4th quarter. Public Employees Retirement Association of Colorado now owns 255,826 shares of the company’s stock valued at $2,671,000 after buying an additional 238,573 shares during the period. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.